Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China

NEXT STORY
Alignment Healthcare Names Dan Peterson as President of Arizona Market
PREV STORY
Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chimerix to Host Annual Investor Update on October 17, 2018

DURHAM, N.C., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel ...

author_avatar
NASDAQ Market News

Radius Health to Present at Leerink Partners 8th Annual Global Healthcare Conference

author_avatar
NASDAQ Market News

TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy

VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation ...

author_avatar
NASDAQ Market News